Bactana Corp. to be Acquired by Kemin Industries, Positioning Innovative Health Technology Company for Global Growth

PR Newswire

Mon, May 12, 2025 at 7:05 PM EDT

Acquisition to help Bactana to realize the full potential of its technology and accelerate market introduction

FARMINGTON, Conn., May 12, 2025 /PRNewswire-PRWeb/ -- Bactana Corp., a research-driven biotechnology company developing groundbreaking advancements in anaerobic bacteria isolation and fermentation, today announced it has agreed to be acquired by Kemin Industries, Inc., a global ingredient manufacturer committed to sustainably transforming the quality of life for 80% of the world through its products and services.

"This acquisition aligns with Kemin's long-term vision to explore emerging technologies in intestinal health and further strengthen our position as an industry leader," said Kimberly Nelson, President of Kemin Nutrisurance.

This acquisition marks a significant milestone for Bactana, building on the foundation it established at Cornell University and its successful development within the UConn Technology Incubation Program (UConn TIP) over the past five years. The resources and support provided by UConn TIP in Farmington, CT, have been instrumental in advancing Bactana's pioneering research and preparing its innovative solutions for market launch.

"We are incredibly grateful to our employees, advisors, and shareholders for their continued support and confidence in our vision over the past six years," said John Kallassy, CEO of Bactana Corp. "This agreement, coupled with Kemin's global reach, will help us better position our technology for global application—particularly in the animal health sector—and improve the well-being of animals, and potentially people, around the world for years to come."

About Bactana Corp
Bactana is a development-stage company at the forefront of anaerobic fermentation and the isolation of postbiotic molecules produced by commensal bacteria in the microbiome. Financially backed by Connecticut Innovations, Bactana's proprietary technology is designed to support metabolic and intestinal health in companion animals, while also offering sustainable solutions to reduce antibiotic use and conserve natural resources in livestock production.

About Kemin Industries
Kemin Industries (http://www.kemin.com) is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human and animal health and nutrition, pet food, aquaculture, nutraceutical, food technologies, crop technologies, textile, biofuel, and animal vaccine industries. Established in 1961, Kemin is a privately held, family-owned-and-operated company with more than 3,000 global employees and operations in 90 countries, including manufacturing facilities in Belgium, Brazil, China, Egypt, India, Italy, San Marino, Singapore, South Africa, and the United States.

Media Contact

John A. Kallassy, Bactana Corp., 203-599-0133, info@bactana.com, https://www.bactana.com

Exciting news from Bactana! We are proud to announce the Canadian Vet Health Product registration of Pawsni™ Metabolic Health, the world's first product derived from the probiotic F. prausnitzii. With over 50% of cats and dogs considered overweight or struggling from metabolic health issues, clinically supported supplements like Pawsni play a crucial role in their well-being. We extend our gratitude to our research team, investors, and supporters who have helped us reach this milestone. Visit www.pawsni.com to learn more or shop. 

Funding will support Bactana’s development of novel microbiome-related products to enhance feed efficiency while also improving the safety of food products derived from animals

Read More>

Farmington startup Bactana developing drugs to combat diabetes in pets, potentially humans > READ MORE

This award enables expansion of Bactana’s leading therapeutic drug candidate to advance treatments for prediabetes and T2 diabetes for companion animals and potentially humans.

READ MORE>

The agreement will provide pet owners in France with access to Bactana’s Pawsni™ Glucose Control, the world’s first product derived from the commensal bacteria Faecalibacterium prausnitzii.

READ MORE>

Bactana is getting closer to bringing its first product to market and finding new uses for its microbiome discovery platform. The firm’s core product initiative – FPS – is based on a naturally occurring collection of ‘pioneer gut colonizers’ selected from the Faecalibacterium prausnitzii bacteria species. In 2018, Bactana received its initial equity financing to develop novel probiotics for ruminants.

Read More> (Featured in Animal Pharm).